Why Intersect ENT is an Example of Hope for the Medtech Industry
Medsider: Learn from Medtech and Healthtech Founders and CEOs - En podcast af Scott Nelson - Onsdage
Kategorier:
The 2.3% medical device tax is burdensome. Regulatory timelines are long (and expensive). Reimbursement is not only decreasing, but also incredibly hard to obtain. Venture capitalists are losing interest in early stage medical device deals. Is it all downhill for medtech? There is no doubt the current healthcare environment is challenging. But certainly not impossible...[read more]Related ArticlesAre Medical Device Models the Key to Building a Lean Medtech Startup?Why Early Stage Medical Device Deals Aren’t as Bad as You May ThinkSubstantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
